. 2022 Dec 9;2022(1):163-172. doi: 10.1182/hematology.2022000334

Table 1.

Pivotal randomized phase 3 trials of monoclonal antibody treatment for MM

Clinical trial	Patient population	Arm (n = number of patients)	Overall response (%)	Median progression-free survival (months)	Hazard ratio (P value)
ALCYONE¹²	Transplant-ineligible NDMM	D-VMP (n = 350)	91	36.4	0.42 (P < .001)
ALCYONE¹²	Transplant-ineligible NDMM	VMP (n = 356)	74	19.3	0.42 (P < .001)
MAIA¹¹	Transplant-ineligible NDMM	D-Rd (n = 368)	92.9	NR	0.53 (P < .001)
MAIA¹¹	Transplant-ineligible NDMM	Rd (n = 369)	81.6	34.4	0.53 (P < .001)
ELOQUENT 1²⁴	Transplant-ineligible NDMM	E-Rd (n = 374)	83	31.4	0.93 (P = .44)
ELOQUENT 1²⁴	Transplant-ineligible NDMM	Rd (n = 374)	79	29.5	0.93 (P = .44)
CASSIOPEIA⁹	Transplant-eligible NDMM	D-VTd (n = 543)	93	NR	0.47 (P < .001)
CASSIOPEIA⁹	Transplant-eligible NDMM	VTd (n = 542)	90	NR	0.47 (P < .001)
GRIFFIN^10,a	Transplant-eligible NDMM	D-RVd (n = 99)	99	NR	Not available
GRIFFIN^10,a	Transplant-eligible NDMM	RVd (n = 97)	92	NR	Not available
GMMG-HD6²³	Transplant-eligible NDMM	E-RVd (n = 555)	B1 81.5%; B2 80.7% (≥VGPR)	B1 66.2%; B2 67.2% (3 y PFS)	Not available (P = .86; no significant difference)
GMMG-HD6²³	Transplant-eligible NDMM	RVd (n = 559)	A1 78.9%; A2 78.2% (≥VGPR)	A1 68.8%; A2 68.5% (3 y PFS)	Not available (P = .86; no significant difference)
GMMG-HD7¹⁹	Transplant-eligible NDMM	I-RVd (n = 329)	MRD 50.1%	NR	Not available (OR = 1.82; P < .001)
GMMG-HD7¹⁹	Transplant-eligible NDMM	RVd (n = 331)	MRD 35.6%	NR	Not available (OR = 1.82; P < .001)
POLLUX⁶	RRMM, at least 1 prior line	D-Rd (n = 286)	93	44.5	0.44 (P < .001)
POLLUX⁶	RRMM, at least 1 prior line	Rd (n = 283)	76	17.5	0.44 (P < .001)
ELOQUENT 2²⁰	RRMM, 1-3 prior lines	E-Rd (n = 321)	79	19.4	0.71 (P < .001)
ELOQUENT 2²⁰	RRMM, 1-3 prior lines	Rd (n = 325)	66	14.9	0.71 (P < .001)
CANDOR⁸	RRMM, 1-3 prior lines	D-Kd (n = 312)	84	NR	0.62 (P = .003)
CANDOR⁸	RRMM, 1-3 prior lines	Kd (n = 154)	75	15.8	0.62 (P = .003)
IKEMA¹⁸	RRMM, 1-3 prior lines	I-Kd (n = 179)	87	NR	0.53 (P < .001)
IKEMA¹⁸	RRMM, 1-3 prior lines	Kd (n = 123)	83	19.2	0.53 (P < .001)
CASTOR⁵	RRMM, at least 1 prior line	D-Vd (n = 251)	83	16.7	0.31 (P < .001)
CASTOR⁵	RRMM, at least 1 prior line	Vd (n = 247)	63	7.1	0.31 (P < .001)
ELOQUENT 3²¹	RRMM, at least 2 prior lines	E-Pd (n = 60)	53	10.3	0.54 (P = .008)
ELOQUENT 3²¹	RRMM, at least 2 prior lines	Pd (n = 57)	26	4.7	0.54 (P = .008)
APOLLO⁷	RRMM, at least 1 prior line	D-Pd (n = 151)	69	12.4	0.63 (P = .0018)
APOLLO⁷	RRMM, at least 1 prior line	Pd (n = 153)	46	6.9	0.63 (P = .0018)
ICARIA-MM¹⁷	RRMM, at least 2 prior lines	I-Pd (n = 154)	63	11.5	0.6 (P = .001)
ICARIA-MM¹⁷	RRMM, at least 2 prior lines	Pd (n = 153)	32	6.5	0.6 (P = .001)

^{^a}

Randomized phase 2 study

Note: This list is not exhaustive for all randomized trials including monoclonal antibodies.

D, daratumumab; d, dexamethasone; E, elotuzumab; I, isatuximab; K, carfilzomib; M, melphalan; OR, odds ratio; P, pomalidomide; p, prednisone; R, lenalidomide; T, thalidomide; V, bortezomib.